Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 2 selected

Guidance programme

Showing 81 to 90 of 791

TitleReference numberPublishedLast updated
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathyTA913
Semaglutide for managing overweight and obesityTA875
Cipaglucosidase alfa with miglustat for treating late-onset Pompe diseaseTA912
Afamelanotide for treating erythropoietic protoporphyriaHST27
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)TA910
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancerTA909
Rimegepant for preventing migraineTA906
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908

Results per page

  1. 10
  2. 25
  3. 50
  4. All